Zhu Ziman, Zhang Rong, Chi Yijia, Li Wenshan, Gong Weijun
Beijing Rehabilitation Hospital, Beijing, China.
Capital Medical University, Beijing, China.
Lasers Med Sci. 2025 May 21;40(1):234. doi: 10.1007/s10103-025-04484-x.
Photobiomodulation can alleviate the severity or delay the development of cognitive impairment through early prevention and intervention. This systematic review summarizes the effectiveness of photobiomodulation in improving cognitive function across various populations. Clinical randomized controlled trials from the establishment of the database to October 2024 were searched in PubMed, Web of Science, EMBASE, and the Cochrane Library according to PRISMA guidelines. Trials comparing the effects of PBM treatment with placebo or sham stimulation on cognitive function in healthy adults or subjects with cognitive impairment were included. Two independent researchers conducted literature screening, data extraction, and quality assessment of the included studies. Meta-analyses were performed using random effects models with Review Manager V.5.4 software. The methodological quality of the studies was evaluated using the Cochrane Risk of Bias tool. Sensitivity analyses were performed using Stata V.15.1 software. A total of 24 randomized trials involving 820 participants met the inclusion criteria. Compared with the control group, PBM treatment showed significant benefits for subjects in terms of global cognitive function (SMD = 0.66, 95% CI: 0.23 to 1.08, P = 0.003), working memory span (SMD = 1.41, 95% CI: 0.78 to 2.04, P < 0.0001), attention (SMD = -1.15, 95% CI: -2.05 to -0.24, P = 0.01) and the reaction time of executive function (SMD = -1.10, 95% CI: -1.86 to -0.33, P = 0.005) aspects. In the subgroup analyses, with the exception of no differences in both reaction time of working memory and accuracy of executive function, cognitive impaired subjects showed some improvement in other all cognitive domains (attention test only for healthy subjects), while healthy subjects showed an insignificant improvement in reaction time of executive function. This meta-analysis found that PBM treatment positively impacts global cognitive function, working memory, and executive function in persons with cognitive impairment, and partially improved global cognitive function, working memory and attention in the healthy population. However, this finding should be treated with caution due to the heterogeneity and limitations of the studies. Registration number: CRD42024552832. Registration data: 2024/06/10.
光生物调节可通过早期预防和干预减轻认知障碍的严重程度或延缓其发展。本系统评价总结了光生物调节对不同人群改善认知功能的有效性。根据PRISMA指南,在PubMed、Web of Science、EMBASE和Cochrane图书馆中检索了从数据库建立到2024年10月的临床随机对照试验。纳入比较光生物调节治疗与安慰剂或假刺激对健康成年人或认知障碍受试者认知功能影响的试验。两名独立研究人员对纳入研究进行了文献筛选、数据提取和质量评估。使用Review Manager V.5.4软件的随机效应模型进行荟萃分析。使用Cochrane偏倚风险工具评估研究的方法学质量。使用Stata V.15.1软件进行敏感性分析。共有24项涉及820名参与者的随机试验符合纳入标准。与对照组相比,光生物调节治疗在总体认知功能(标准化均数差[SMD]=0.66,95%置信区间[CI]:0.23至1.08,P=0.003)、工作记忆广度(SMD=1.41,95%CI:0.78至2.04,P<0.0001)、注意力(SMD=-1.15,95%CI:-2.05至-0.24,P=0.01)和执行功能反应时间(SMD=-1.10,95%CI:-1.86至-0.33,P=0.005)方面对受试者显示出显著益处。在亚组分析中,除工作记忆反应时间和执行功能准确性均无差异外,认知障碍受试者在所有其他认知领域均有一定改善(仅对健康受试者进行注意力测试),而健康受试者在执行功能反应时间方面有不显著改善。该荟萃分析发现,光生物调节治疗对认知障碍患者的总体认知功能、工作记忆和执行功能有积极影响,并部分改善了健康人群的总体认知功能、工作记忆和注意力。然而,由于研究的异质性和局限性,这一发现应谨慎对待。注册号:CRD42024552832。注册日期:2024年6月10日。